# A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Source: https://onco.cc/trials/nct05608044/  
OnCo record `nct05608044` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Botensilimab in colorectal cancer, run by Agenus Inc., active and no longer recruiting.

## Summary

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer is a phase 2 interventional study registered as NCT05608044 by Agenus Inc., with 234 participants enrolled, started 2022-11-30 and due to reach its primary completion in 2027-09. Interventions recorded: Botensilimab, Balstilimab, Standard of Care. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05608044
- Phase: 2
- Setting: A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer
- Sponsor: Agenus Inc.
- Enrolled: 234

## Sources

- ClinicalTrials.gov NCT05608044: https://clinicaltrials.gov/study/NCT05608044

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Balstilimab](https://onco.cc/drugs/balstilimab/), [Botensilimab](https://onco.cc/drugs/botensilimab/)
- companies: [Agenus](https://onco.cc/companies/agenus/)

---
JSON: https://onco.cc/api/v1/entities/nct05608044.json